First-line IBRANCE + aromatase inhibitor*

Palbociclib (IBRANCE) + aromatase inhibitor may be considered as a treatment option for first-line therapy for postmenopausal women with HR+/HER2- MBC1†‡
Category 1: Based on high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.1
If there is disease progression while on CDK4/6 inhibitor therapy, there are no data to support an additional line of therapy with another CDK4/6-containing regimen.1
*IBRANCE was studied with letrozole but is FDA approved for use with any aromatase inhibitor as first-line treatment for postmenopausal women with HR+/HER2- MBC.
MBC=metastatic breast cancer; NCCN®=National Comprehensive Cancer Network®.
REFERENCE
1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed April 13, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.